T. Rowe Price Associates’s Ambrx Biopharma Inc AMAM Stock Holding History

T. Rowe Price Associates’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,084,247	Closed	-$15.4M	–	2997
2023 Q4	$15.4M	Buy	1,084,247 +262,683	+32%	+$2.98M	﹤0.01%	1007
2023 Q3	$9.45M	Sell	821,564 -107,753	-12%	-$1.47M	﹤0.01%	1080
2023 Q2	$15.3M	Buy	929,317 +718,690	+341%	+$9.04M	﹤0.01%	1005
2023 Q1	$1.88M	Buy	+210,627	New	+$1.06M	﹤0.01%	1479

T. Rowe Price Associates's AMAM Position: Q1 2024 in Review

T. Rowe Price Associates sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 1,084,247 shares — an estimated $15.4M sold.

T. Rowe Price Associates first reported a position in AMAM in Q1 2023 and held it in 4 quarters. The position peaked at $15.4M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

T. Rowe Price Associates reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
T. Rowe Price Associates sold 1,084,247 Ambrx Biopharma Inc shares in Q1 2024, an estimated $15.4M.
T. Rowe Price Associates first reported a position in Ambrx Biopharma Inc in Q1 2023 and held it in 4 quarters.
T. Rowe Price Associates's Ambrx Biopharma Inc position peaked at $15.4M in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.